The Cytometry and Antibody Technology (CAT) Facility serves the University of Chicago Comprehensive Cancer Center (UCCCC) membership by providing all of the tools necessary to measure properties of cells and their products. The Fitch Monoclonal Subcore (FMS) develops the reagents used to label the cells, whereas the Flow Cytometry Subcore (FCS) provides the technology and staff expertise to use these reagents for experimental measurements. During the past 35 years, antibodies have become reliable and necessary tools in the continuously growing interdisciplinary approach to basic and clinical research, as well as the diagnosis, and treatment of disease. Antibody technology and its usage have evolved concurrently with flow and image cytometry and has become the dominant tool for the identification and classification of cells and cellular products, especially in the areas of cancer research. The Facility is utilized by UCCCC investigators in many areas of study involved in the basic and translational research of cellular phenotype and function.
The specific aim of the CAT Facility is to provide instrumentation and antibodies for the analytical detection of subcellular components and proteins using a range of fluorescence and non-fluorescence-based detection technologies. Further, the CAT Facility is designed to meet the wide-spread needs for specialized cytometric analysis and continues to respond to the demand for new and improved technology. Among these improvements include an expanding Antibody/Hybridoma Bank that provides commonly used, highest quality purified antibodies, pre-titered conjugated antibodies for flow cytometry, and hybridoma lines to UCCCC investigators. Cytometric technology improvements include the latest in high-speed cell sorting, multi-laser analyzers for performing polychromatic flow cytometry. Image-based cytometers, and bead-based analyte detectors.
Flow Cytometry technology and fluorescently labeled antibodies are the predominant tools utilized in the study and diagnosing of various cancers, including leukemias and lymphomas. Nearly every cancer-related research project utilizes these technologies in one form or another making them and their related services, indispensible to the future of cancer prevention and treatment.
|Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73|
|Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24|
|Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334|
|Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083|
|Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680|
|Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966|
|Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437|
|Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70|
|Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:|
|Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977|
Showing the most recent 10 out of 668 publications